4DMedical Future Growth
Future criteria checks 2/6
4DMedical is forecast to grow earnings and revenue by 46% and 66.8% per annum respectively. EPS is expected to grow by 55.3% per annum. Return on equity is forecast to be -10.5% in 3 years.
Key information
46.0%
Earnings growth rate
55.3%
EPS growth rate
Healthcare Services earnings growth | 22.1% |
Revenue growth rate | 66.8% |
Future return on equity | -10.5% |
Analyst coverage | Low |
Last updated | 30 Sep 2024 |
Recent future growth updates
Recent updates
Here's Why We're Watching 4DMedical's (ASX:4DX) Cash Burn Situation
Sep 21We're Keeping An Eye On 4DMedical's (ASX:4DX) Cash Burn Rate
May 084DMedical Limited's (ASX:4DX) CEO Compensation Is Looking A Bit Stretched At The Moment
Oct 26Here's Why We're Not At All Concerned With 4DMedical's (ASX:4DX) Cash Burn Situation
Jun 16We Think 4DMedical (ASX:4DX) Needs To Drive Business Growth Carefully
Feb 01Is 4DMedical (ASX:4DX) In A Good Position To Deliver On Growth Plans?
Oct 18We're Hopeful That 4DMedical (ASX:4DX) Will Use Its Cash Wisely
Jul 05We Think 4DMedical (ASX:4DX) Can Afford To Drive Business Growth
Jan 27Here's Why We're Not Too Worried About 4DMedical's (ASX:4DX) Cash Burn Situation
Jun 05Is 4DMedical Limited's (ASX:4DX) Shareholder Ownership Skewed Towards Insiders?
Feb 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 57 | -8 | -6 | -3 | 3 |
6/30/2026 | 36 | -14 | -12 | -9 | 3 |
6/30/2025 | 13 | -32 | -29 | -27 | 3 |
6/30/2024 | 4 | -36 | -32 | -31 | N/A |
3/31/2024 | 2 | -33 | -33 | -32 | N/A |
12/31/2023 | 1 | -31 | -34 | -32 | N/A |
9/30/2023 | 1 | -31 | -29 | -28 | N/A |
6/30/2023 | 1 | -31 | -24 | -23 | N/A |
3/31/2023 | 1 | -30 | -19 | -18 | N/A |
12/31/2022 | 1 | -28 | -15 | -13 | N/A |
9/30/2022 | 1 | -26 | -22 | -19 | N/A |
6/30/2022 | 1 | -25 | -29 | -25 | N/A |
3/31/2022 | 1 | -23 | -28 | -24 | N/A |
12/31/2021 | 0 | -21 | -26 | -23 | N/A |
9/30/2021 | 0 | -21 | -21 | -19 | N/A |
6/30/2021 | 0 | -21 | -15 | -15 | N/A |
3/31/2021 | 0 | -26 | -16 | -15 | N/A |
12/31/2020 | 0 | -30 | -16 | -15 | N/A |
9/30/2020 | 1 | -26 | -12 | -11 | N/A |
6/30/2020 | 1 | -22 | -9 | -8 | N/A |
3/31/2020 | 2 | -16 | -8 | -7 | N/A |
12/31/2019 | 2 | -9 | -7 | -6 | N/A |
9/30/2019 | 1 | -8 | -7 | -6 | N/A |
6/30/2019 | 1 | -6 | -7 | -6 | N/A |
6/30/2018 | 1 | -4 | -5 | -3 | N/A |
6/30/2017 | 1 | -4 | N/A | -2 | N/A |
12/31/2015 | 0 | -1 | N/A | -1 | N/A |
12/31/2014 | 0 | 0 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4DX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4DX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4DX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4DX's revenue (66.8% per year) is forecast to grow faster than the Australian market (5.9% per year).
High Growth Revenue: 4DX's revenue (66.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4DX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 18:17 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
4DMedical Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Hester | Bell Potter |
Thomas Godfrey | Ord Minnett Limited |